GO:0038171 cannabinoid signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038171 (cannabinoid signaling pathway) is a biological process defined as a G protein-coupled receptor signaling pathway initiated by a cannabinoid binding to its receptor on the cell surface and ending with regulation of a downstream cellular process such as transcription [1,4].
• The pathway is activated by endocannabinoids such as anandamide and 2-arachidonoylglycerol, and by phytocannabinoids such as delta-9-tetrahydrocannabinol, all of which act on cannabinoid receptors CB1 (CNR1) and CB2 (CNR2) [4,6].
• Cannabinoid signaling is not confined to neurons; it operates in glial cells, astrocytes, immune cells, and tumor cells, where it modulates proliferation, migration, differentiation, and cytokine release [2,3,7].
• Dysregulation of cannabinoid signaling is implicated in cancer, glioma progression, neuroinflammation, and behavioral disorders, making it a target for therapeutic and mechanistic studies [1,2,3,8].
• Key research methods include receptor-binding assays, cAMP and beta-arrestin reporter assays, calcium imaging, electrophysiology, RNA-seq, and CRISPR-based genetic models [4,5,7].
• CRISPR knockout, point-mutation, knock-in, and overexpression cell models enable causal dissection of CNR1, CNR2, and downstream effectors in cannabinoid signaling [1,3,8].
Description
The cannabinoid signaling pathway (GO:0038171) is a biological process in which a cannabinoid ligand binds to a cell-surface G protein-coupled receptor and triggers intracellular signaling that ultimately regulates downstream cellular processes, including transcription [1,4]. This pathway is initiated by chemically diverse cannabinoids, a class that includes endocannabinoids such as anandamide and 2-arachidonoylglycerol, and phytocannabinoids such as delta-9-tetrahydrocannabinol [4,6]. The receptors most strongly associated with this pathway are CB1 (encoded by CNR1) and CB2 (encoded by CNR2), which couple to Gi/o proteins and modulate adenylyl cyclase, ion channels, and kinase cascades [4,7]. Because cannabinoid signaling influences neuronal excitability, glial function, immune responses, and tumor cell behavior, it is a high-value area for both basic and translational research [2,3,7]. Understanding GO:0038171 helps researchers interpret how cannabinoid receptor activation is converted into context-dependent cellular outcomes, and how this process can be perturbed in disease [1,8].
cannabinoid signaling pathway At A Glance
| GO ID | GO:0038171 |
|---|---|
| GO term | cannabinoid signaling pathway |
| Ontology | biological_process |
| Synonym | cannabinoid-activated signaling pathway; cannabinoid-mediated signaling pathway; cannabinoid receptor signaling pathway |
| Major function | G protein-coupled receptor signaling initiated by cannabinoid binding at the cell surface, leading to regulation of downstream cellular processes such as transcription [1,4] |
| Ligand class | Endocannabinoids (e.g., anandamide, 2-arachidonoylglycerol) and phytocannabinoids (e.g., delta-9-tetrahydrocannabinol) [4,6] |
| Primary receptors | CB1 (CNR1) and CB2 (CNR2), with additional candidate receptors such as GPR55 and GPR18 discussed in the literature [4,5] |
| Cellular contexts | Neurons, astrocytes, glial cells, immune cells, and tumor cells [2,3,7] |
| Downstream outputs | Modulation of adenylyl cyclase, ion channels, MAPK/ERK, PI3K/AKT, and transcriptional regulation [1,3,7] |
What Is GO:0038171?
According to the QuickGO definition, GO:0038171 (cannabinoid signaling pathway) is a G protein-coupled receptor signaling pathway initiated by a cannabinoid binding to its receptor on the cell surface, and ending with the regulation of a downstream cellular process, e.g. transcription. Cannabinoids are a class of diverse chemical compounds that include the endocannabinoids and the phytocannabinoids. In practice, this means the pathway begins with ligand-receptor engagement at the plasma membrane and proceeds through heterotrimeric G protein activation and downstream effector modulation, ultimately altering cellular behavior such as gene expression, excitability, or secretion [1,4,7].
Why Is cannabinoid signaling pathway Important in Cell Biology?
Cannabinoid signaling is important because it is a widespread neuromodulatory and immunomodulatory system that affects synaptic transmission, glial activity, inflammation, and cell survival [2,4,7]. Its dysregulation has been linked to cancer progression, glioma biology, neuroinflammatory conditions, and behavioral phenotypes, making it relevant to oncology, neuroscience, and immunology [1,2,3,8]. Because the pathway converges on GPCR-driven cascades that can be measured with standard assays, it is also a tractable model for studying ligand bias, receptor crosstalk, and downstream transcriptional control [4,7].
• Regulates synaptic transmission and neuronal excitability through CB1 receptor signaling.
• Modulates astrocyte and glial functions that influence behavior and neuroinflammation [2,7].
• Influences tumor cell proliferation, migration, and survival in cancer and glioma models [1,3].
• Controls immune cell activity and cytokine release through CB2 receptor signaling [7,8].
• Provides a paradigm for studying GPCR ligand bias and downstream transcriptional regulation.
• Is a therapeutic target in pain, inflammation, neurodegeneration, and cancer [1,8].
• Can be probed with CRISPR knockout, knock-in, and overexpression models to establish causality [1,3].
• Connects endocannabinoid metabolism to receptor activation and cellular outcomes.
• Is relevant to phytocannabinoid pharmacology, including compounds such as cannabigerol.
• Offers measurable readouts such as cAMP, beta-arrestin recruitment, calcium flux, and gene expression [4,7].
What Happens During cannabinoid signaling pathway?
Ligand binding and receptor activation
In simple terms: A cannabinoid molecule docks onto a receptor on the cell surface, switching the receptor on.
The pathway begins when a cannabinoid ligand binds to a cell-surface cannabinoid receptor, most commonly CB1 (CNR1) or CB2 (CNR2). Endocannabinoids such as anandamide and 2-arachidonoylglycerol are synthesized and released in a stimulus-dependent manner and act locally on these receptors. Phytocannabinoids such as delta-9-tetrahydrocannabinol also activate these receptors, and additional phytocannabinoids such as cannabigerol are studied for their receptor interactions. Ligand binding induces conformational changes in the receptor that enable coupling to heterotrimeric G proteins.
G protein coupling and second messenger modulation
In simple terms: The activated receptor talks to G proteins inside the cell, which then change the levels of small signaling molecules.
Cannabinoid receptors predominantly couple to Gi/o proteins, which inhibit adenylyl cyclase and reduce cyclic AMP levels [4,7]. This coupling also leads to modulation of ion channels, including inhibition of voltage-gated calcium channels and activation of G protein-gated inwardly rectifying potassium channels. These second messenger and ion channel changes alter neuronal excitability and transmitter release. In glial cells, similar G protein-dependent mechanisms regulate glial signaling and cytokine release.
Downstream kinase cascades and transcriptional regulation
In simple terms: The signal travels further inside the cell and can switch genes on or off.
Beyond second messengers, cannabinoid receptor activation engages kinase cascades such as MAPK/ERK and PI3K/AKT, which regulate cell proliferation, survival, and migration [1,3]. These cascades can converge on transcription factors and thereby change gene expression programs. In glioma cells, cannabinoid signaling has been shown to influence proliferation and survival pathways. In cancer more broadly, cannabinoid signaling can modulate tumor cell behavior through receptor-dependent mechanisms.
Cell-type-specific outcomes in neurons and glia
In simple terms: The same pathway can do different things depending on the cell type.
In neurons, cannabinoid signaling acts as a retrograde messenger that suppresses neurotransmitter release and modulates synaptic plasticity. In astrocytes and other glial cells, cannabinoid signaling participates in neuron-glia communication and can influence behavior. Glial cannabinoid signaling also contributes to neuroinflammatory responses. These cell-type-specific outcomes explain why the pathway is studied in both physiological and pathological contexts [2,7].
Termination and desensitization
In simple terms: The signal is switched off when the receptor is internalized or the ligand is removed.
Cannabinoid signaling is terminated by ligand degradation and by receptor desensitization and internalization, processes that involve receptor phosphorylation and beta-arrestin recruitment. Endocannabinoids are degraded by specific enzymes, which limits the duration of receptor activation. These regulatory steps are important because prolonged or dysregulated signaling can alter cellular responses [4,7].
Key Genes Involved in GO:0038171 cannabinoid signaling pathway
The following genes and proteins are central to cannabinoid signaling pathway research, spanning receptors, endocannabinoid metabolic enzymes, and downstream effectors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CNR1 | Encodes CB1 receptor, the primary neuronal cannabinoid receptor | Central to studies of synaptic modulation and neurobehavioral effects |
| CNR2 | Encodes CB2 receptor, mainly expressed in immune cells | Target for immunomodulation and inflammation research |
| GPR55 | Candidate cannabinoid-sensitive receptor | Studied for non-CB1/CB2 cannabinoid responses |
| GPR18 | Candidate cannabinoid-sensitive receptor | Explored in endocannabinoid-related signaling |
| FAAH | Degrades anandamide | Regulates endocannabinoid tone |
| MGLL | Degrades 2-arachidonoylglycerol | Controls endocannabinoid levels |
| DAGL | Synthesizes 2-arachidonoylglycerol | Endocannabinoid biosynthesis |
| NAPEPLD | Synthesizes anandamide | Endocannabinoid biosynthesis |
| GNAI1 | Gi alpha subunit | Mediates Gi/o-coupled inhibition of adenylyl cyclase |
| GNAI2 | Gi alpha subunit | Mediates Gi/o-coupled signaling |
| GNAI3 | Gi alpha subunit | Mediates Gi/o-coupled signaling |
| ARRB1 | Beta-arrestin 1 | Receptor desensitization and internalization |
| ARRB2 | Beta-arrestin 2 | Receptor desensitization and biased signaling |
| MAPK1 | ERK2 kinase | Downstream kinase cascade [1,3] |
| MAPK3 | ERK1 kinase | Downstream kinase cascade [1,3] |
| AKT1 | PI3K/AKT pathway kinase | Cell survival signaling [1,3] |
| ADCY1 | Adenylyl cyclase | cAMP production modulated by cannabinoid receptors |
How Is cannabinoid signaling pathway Regulated?
Cannabinoid signaling is regulated at multiple levels. Receptor availability and sensitivity are controlled by desensitization and internalization involving beta-arrestins. Endocannabinoid levels are regulated by synthesis and degradation enzymes such as FAAH and MGLL. Downstream, kinase cascades including MAPK/ERK and PI3K/AKT modulate the intensity and duration of cellular responses [1,3]. In glial cells, cannabinoid signaling is also subject to regulation by inflammatory mediators and cell-cell communication.
cannabinoid signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CNR1 | Cancer and neurobehavioral disorders | CNR1 knockout and point-mutation cell lines [1,4] |
| CNR2 | Inflammation and immune disorders | CNR2 knockout immune cell models |
| FAAH | Pain and neuroinflammation | FAAH knockout or overexpression models |
| MGLL | Metabolic and inflammatory conditions | MGLL knockout cell lines |
| GPR55 | Cancer and inflammation | GPR55 knockout and overexpression models |
Cannabinoid signaling in cancer
Cannabinoid signaling has been implicated in multiple cancer types, where it can influence proliferation, migration, and survival. Receptor-dependent effects are context-specific, and both pro- and anti-tumor outcomes have been reported depending on the model. These findings support the use of cannabinoid pathway components as experimental targets in oncology research.
Cannabinoid signaling in glioma
In glioma cells, cannabinoid signaling modulates proliferation, survival, and migration through receptor-mediated pathways. Glioma models are widely used to dissect how CB1 and CB2 activation affects tumor cell behavior. This makes glioma a key disease context for studying GO:0038171.
Cannabinoid signaling in neuroinflammation and behavior
Astroglial cannabinoid signaling contributes to neuron-glia communication and has been linked to behavioral outcomes. Glial cannabinoid signaling also participates in neuroinflammatory responses. These roles connect the pathway to neurological and psychiatric research [2,7].
Cannabinoid signaling in health and disease
Cannabinoid signaling is involved in a broad range of physiological and pathological processes, including pain, inflammation, and metabolic regulation. Its widespread actions make it relevant to multiple therapeutic areas. Understanding its disease-specific roles requires careful genetic and pharmacological dissection.
From cannabinoid signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CNR1 mediate cannabinoid-induced signaling? | CNR1 knockout cell line [1,4] |
| Does a specific CNR1 variant alter ligand response? | CNR1 point-mutation knock-in |
| Can a tagged receptor be tracked in live cells? | Tagged CNR1 knock-in |
| Does CNR2 overexpression enhance immune modulation? | CNR2 overexpression cell line |
| Which downstream genes respond to cannabinoid treatment? | RNA-seq after cannabinoid stimulation [1,3] |
| Does FAAH loss alter endocannabinoid tone? | FAAH knockout model |
How to Study the cannabinoid signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| cAMP assay | Gi/o-mediated inhibition of adenylyl cyclase | Receptor activation profiling |
| Beta-arrestin recruitment | Receptor desensitization and biased signaling | Ligand bias studies |
| Calcium imaging | Intracellular calcium changes | Neuronal signaling studies |
| Electrophysiology | Ion channel and synaptic activity | Neuronal excitability |
| RNA-seq | Transcriptional changes | Downstream gene expression [1,3] |
| CRISPR knockout | Loss-of-function effects | Causal gene testing [1,3] |
| CRISPR knock-in | Tagged or mutant protein expression | Receptor tracking and variant studies |
| Overexpression | Gain-of-function effects | Pathway activation studies |
Receptor binding and signaling assays
Cannabinoid receptor activation can be measured using radioligand binding, cAMP assays, and beta-arrestin recruitment assays. These methods quantify ligand potency and efficacy at CB1 and CB2. They are foundational for characterizing cannabinoid pathway activity.
Calcium imaging and electrophysiology
Calcium imaging and electrophysiology are used to measure the effects of cannabinoid signaling on neuronal excitability and synaptic transmission. These approaches capture rapid signaling events downstream of receptor activation. They are especially useful in primary neuronal cultures and brain slices.
Transcriptomics and pathway profiling
RNA-seq and pathway profiling can identify transcriptional changes induced by cannabinoid signaling [1,3]. These methods help link receptor activation to downstream gene expression programs. They are widely used in cancer and glioma models [1,3].
Genetic perturbation with CRISPR
CRISPR knockout, knock-in, and overexpression models allow causal testing of cannabinoid pathway genes [1,3]. These models can be combined with signaling assays to determine gene function [1,3]. They are essential for distinguishing correlation from causation [1,3].
How CRISPR Can Be Used to Study GO:0038171 cannabinoid signaling pathway
Knockout
CRISPR knockout of CNR1, CNR2, or downstream effectors can abolish specific cannabinoid signaling responses and reveal which components are required [1,3]. Knockout models are widely used to test receptor dependence of cellular outcomes [1,3].
Point Mutation
Point-mutation knock-in can be used to study receptor variants or catalytic residues that affect cannabinoid signaling. These models help link specific amino acid changes to altered ligand binding or signaling.
Knock-in
Tagged knock-in of cannabinoid receptors enables live-cell imaging and biochemical tracking of receptor localization and trafficking. This approach is valuable for studying receptor internalization and desensitization.
Overexpression
Overexpression of cannabinoid receptors or downstream effectors can amplify pathway activity and reveal gain-of-function phenotypes. This is useful for studying immune modulation and tumor cell behavior.
How EDITGENE Supports cannabinoid signaling pathway Research
Researchers studying cannabinoid signaling pathway-related genes often need to determine whether a candidate gene is causally involved in receptor-driven cellular responses, and CRISPR-based models provide a direct way to test this. EDITGENE supports this work with knockout, point-mutation, knock-in, overexpression cell models, and CRISPR library screening combined with bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for cannabinoid signaling pathway research.
Frequently Asked Questions About cannabinoid signaling pathway
What is the cannabinoid signaling pathway (GO:0038171)?
It is a G protein-coupled receptor signaling pathway initiated by a cannabinoid binding to its receptor on the cell surface and ending with regulation of a downstream cellular process such as transcription [1,4].
What genes are involved in cannabinoid signaling?
Key genes include CNR1 (CB1), CNR2 (CB2), GPR55, GPR18, FAAH, MGLL, DAGL, NAPEPLD, GNAI1-3, ARRB1, ARRB2, MAPK1, MAPK3, AKT1, and ADCY1 [4,5,6].
What are the main receptors in cannabinoid signaling?
The best-characterized receptors are CB1 (CNR1) and CB2 (CNR2), with additional candidate receptors such as GPR55 and GPR18 under study [4,5].
What are endocannabinoids?
Endocannabinoids are endogenous lipid signaling molecules such as anandamide and 2-arachidonoylglycerol that activate cannabinoid receptors.
How is cannabinoid signaling studied in the lab?
Common methods include cAMP assays, beta-arrestin recruitment, calcium imaging, electrophysiology, RNA-seq, and CRISPR-based genetic models [1,3,4].
What diseases are linked to cannabinoid signaling?
Cannabinoid signaling has been implicated in cancer, glioma, neuroinflammation, and behavioral disorders [1,2,3,8].
How does cannabinoid signaling affect neurons?
It acts as a retrograde messenger that suppresses neurotransmitter release and modulates synaptic plasticity.
What is the role of glial cannabinoid signaling?
Glial cannabinoid signaling contributes to neuron-glia communication, behavior, and neuroinflammatory responses [2,7].
Can CRISPR be used to study cannabinoid signaling?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models can test causal roles of cannabinoid pathway genes [1,3,4].
What is the difference between CB1 and CB2 receptors?
CB1 (CNR1) is primarily neuronal, while CB2 (CNR2) is mainly expressed in immune cells and modulates inflammation [4,7].
Conclusion
GO:0038171 (cannabinoid signaling pathway) is a biologically important GPCR pathway that translates cannabinoid ligand binding into diverse cellular outcomes, including transcriptional regulation [1,4]. Its roles in neurons, glia, immune cells, and tumors make it a rich area for mechanistic and translational research [2,3,7]. CRISPR-based models and modern signaling assays provide powerful tools to dissect this pathway and its disease relevance [1,3,8].
References
- 1. Das S et al.. 2019. Cannabinoid Signaling in Cancer.. Adv Exp Med Biol 1162:51-61 PMID: 31332734
- 2. Ramon-Duaso C et al.. 2023. Astroglial cannabinoid signaling and behavior.. Glia 71(1):60-70 PMID: 35293647
- 3. Ellert-Miklaszewska A et al.. 2020. Cannabinoid Signaling in Glioma Cells.. Adv Exp Med Biol 1202:223-241 PMID: 32034716
- 4. Mackie K. 2008. Cannabinoid receptors: where they are and what they do.. J Neuroendocrinol 20 Suppl 1:10-4 PMID: 18426493
- 5. Li S et al.. 2024. Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.. Molecules 29(22) PMID: 39598860
- 6. Mechoulam R et al.. 1998. Endocannabinoids.. Eur J Pharmacol 359(1):1-18 PMID: 9831287
- 7. Stella N. 2004. Cannabinoid signaling in glial cells.. Glia 48(4):267-77 PMID: 15390110
- 8. Lu Y et al.. 2017. Cannabinoid signaling in health and disease.. Can J Physiol Pharmacol 95(4):311-327 PMID: 28263083
